The role of IL-33-dependent inflammation in the tumor microenvironment

Frontiers in Immunology

Volumn 7, Issue JAN, 2017, Pages

  Wasmer, Marie Hélène ^a   Krebs, Philippe ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cancer; Inflammation; Interleukin 33; Therapy; Tumor microenvironment

Indexed keywords

ALARMIN; CANCER VACCINE; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33; TUMOR MARKER;

BILE DUCT CARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; METASTASIS; MYELOPROLIFERATIVE NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; REVIEW; SPATIOTEMPORAL ANALYSIS; STOMACH CANCER; TRANSCRIPTION REGULATION; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 85012036961     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00682     Document Type: Review

References (127)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100(1):57-70. doi: 10.1016/S0092-8674(00)81683-9.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013.
3. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 21(3):309-22. doi:10.1016/j.ccr.2012.02.022.
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell (2010) 140(6):883-99. doi:10.1016/j.cell.2010.01.025.
5. Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer (2013) 4(1):66-83. doi:10.7150/jca.5112.
6. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res (2008) 25(9):2097-116. doi:10.1007/s11095-008-9661-9.
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313(5795):1960-4. doi:10.1126/science.1129139.
8. Zhu Y, Ju S, Chen E, Dai S, Li C, Morel P, et al. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol (2010) 185(6):3174-83. doi:10.4049/jimmunol.1000749.
9. Chen LJ, Zheng X, Shen YP, Zhu YB, Li Q, Chen J, et al. Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. Cancer Immunol Immunother (2013) 62(3):553-61. doi:10.1007/s00262-012-1358-6.
10. Kim S, Karin M. Role of TLR2-dependent inflammation in metastatic progression. Ann N Y Acad Sci (2011) 1217:191-206. doi:10.1111/j.1749-6632.2010.05882.x.
11. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med (2000) 248:171-83. doi:10.1046/j.1365-2796.2000.00742.x.
12. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med (1990) 323(18):1228-33. doi:10.1056/NEJM199011013231802.
13. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol (2005) 100(12):2724-9. doi:10.1111/j.1572-0241.2005.00287.x.
14. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature (2008) 454(7203):436-44. doi:10.1038/nature07205.
15. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol (2013) 33(Suppl 1):S79-84. doi:10.1007/s10875-012-9847-0.
16. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 23(5):479-90. doi:10.1016/j.immuni.2005.09.015.
17. LamkanfiM, Dixit VM. IL-33 raises alarm. Immunity (2009) 31(1):5-7. doi:10.1016/j.immuni.2009.06.011.
18. Lefrancais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A (2012) 109(5):1673-8. doi:10.1073/pnas.1115884109.
19. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol (2010) 10(2):103-10. doi:10.1038/nri2692.
20. Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol (2012) 188(7):3488-95. doi:10.4049/jimmunol.1101977.
21. Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol (2014) 31:31-7. doi:10.1016/j.coi.2014.09.004.
22. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol (2011) 187(4):1609-16. doi:10.4049/jimmunol.1003080.
23. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J (1994) 13(5):1176-88.
24. Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem (1999) 264(2):397-406. doi:10.1046/j.1432-1327.1999.00615.x.
25. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem (2007) 282(36):26369-80. doi:10.1074/jbc. M704916200.
26. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (2011) 8(1):22. doi:10.1186/1476-9255-8-22.
27. Brunner SM, Schiechl G, Falk W, Schlitt HJ, Geissler EK, Fichtner-Feigl S. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int (2011) 24(10):1027-39. doi:10.1111/j.1432-2277.2011.01306.x.
28. Duan L, Chen J, Zhang H, Yang H, Zhu P, Xiong A, et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol Med (2012) 18:753-61. doi:10.2119/molmed.2011.00428.
29. Liang Y, Jie Z, Hou L, Aguilar-Valenzuela R, Vu D, Soong L, et al. IL-33 induces nuocytes and modulates liver injury in viral hepatitis. J Immunol (2013) 190(11):5666-75. doi:10.4049/jimmunol.1300117.
30. Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert EA, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature (2014) 513(7519):564-8. doi:10.1038/nature13577.
31. Layland LE, Mages J, Loddenkemper C, Hoerauf A, Wagner H, Lang R, et al. Pronounced phenotype in activated regulatory T cells during a chronic helminth infection. J Immunol (2010) 184(2):713-24. doi:10.4049/jimmunol.0901435.
32. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A special population of regulatory T cells potentiates muscle repair. Cell (2013) 155(6):1282-95. doi:10.1016/j.cell.2013.10.054.
33. McHedlidze T, Waldner M, Zopf S, Walker J, Rankin AL, Schuchmann M, et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity (2013) 39(2):357-71. doi:10.1016/j.immuni.2013.07.018.
34. Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, et al. Interleukin-33 and interferon-gamma counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity (2015) 43(1):161-74. doi:10.1016/j.immuni.2015.05.019.
35. Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med (Berl) (2016) 94(5):535-43. doi:10.1007/s00109-016-1397-0.
36. Leemans CR, Braakhuis BJ, BrakenhoffRH. The molecular biology of head and neck cancer. Nat Rev Cancer (2011) 11(1):9-22. doi:10.1038/nrc2982.
37. Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol (2013) 231(2):180-9. doi:10.1002/path.4226.
38. Ishikawa K, Yagi-Nakanishi S, Nakanishi Y, Kondo S, Tsuji A, Endo K, et al. Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue. Auris Nasus Larynx (2014) 41(6):552-7. doi:10.1016/j.anl.2014.08.007.
39. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer (2014) 14(8):535-46. doi:10.1038/nrc3775.
40. Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest (2013) 123(9):3967-82. doi:10.1172/JCI65570.
41. Makrinioti H, Toussaint M, Jackson DJ, Walton RP, Johnston SL. Role of interleukin 33 in respiratory allergy and asthma. Lancet Respir Med (2014) 2(3):226-37. doi:10.1016/S2213-2600(13)70261-3.
42. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol (2016) 16(11):676-89. doi:10.1038/nri.2016.95.
43. Wang C, Chen Z, Bu X, Han Y, Shan S, Ren T, et al. IL-33 signaling fuels outgrowth and metastasis of human lung cancer. Biochem Biophys Res Commun (2016) 479(3):461-8. doi:10.1016/j.bbrc.2016.09.081.
44. Akimoto M, Hayashi JI, Nakae S, Saito H, Takenaga K. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. Cell Death Dis (2016) 7:e2057. doi:10.1038/cddis.2015.418.
45. Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, et al. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol (2016) 17(8):e347-62. doi:10.1016/S1470-2045(16)30123-1.
46. Ha CT, Li XH, Fu D, Moroni M, Fisher C, Arnott R, et al. Circulating interleukin-18 as a biomarker of total-body radiation exposure in mice, minipigs, and nonhuman primates (NHP). PLoS One (2014) 9(10):e109249. doi:10.1371/journal.pone.0109249.
47. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (2010) 46(4):765-81. doi:10.1016/j.ejca.2009.12.014.
48. Lu X, Kang Y. Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia (2007) 12(2-3):153-62. doi:10.1007/s10911-007-9047-3.
49. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol (2014) 382(1):673-82. doi:10.1016/j.mce.2013.06.003.
50. Liu J, Shen JX, Hu JL, Huang WH, Zhang GJ. Significance of interleukin-33 and its related cytokines in patients with breast cancers. Front Immunol (2014) 5:141. doi:10.3389/fimmu.2014.00141.
51. Kim JY, Lim SC, Kim G, Yun HJ, Ahn SG, Choi HS. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene (2015) 34(38):4928-38. doi:10.1038/onc.2014.418.
52. Yang ZP, Ling DY, Xie YH, Wu WX, Li JR, Jiang J, et al. The association of serum IL-33 and sST2 with breast cancer. Dis Markers (2015) 2015:516895. doi:10.1155/2015/516895.
53. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol (2011) 41(7):1902-12. doi:10.1002/eji.201141417.
54. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer (2014) 134(7):1669-82. doi:10.1002/ijc.28481.
55. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 66(2):1123-31. doi:10.1158/0008-5472.CAN-05-1299.
56. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 20(15):4115-27. doi:10.3748/wjg.v20.i15.4115.
57. Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: a comprehensive review. World J Hepatol (2015) 7(26):2648-63. doi:10.4254/wjh.v7.i26.2648.
58. Zhang P, Liu XK, Chu Z, Ye JC, Li KL, Zhuang WL, et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res (2012) 40(5):1654-61. doi:10.1177/030006051204000504.
59. Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol (2013) 6(3):311-8. doi:10.1593/tlo.12418.
60. Yang Y, Wang JB, Li YM, Zhao YU, Wang R, Wu Q, et al. Role of IL-33 expression in oncogenesis and development of human hepatocellular carcinoma. Oncol Lett (2016) 12(1):429-36. doi:10.3892/ol.2016.4622.
61. Brunner SM, Rubner C, Kesselring R, Martin M, Griesshammer E, Ruemmele P, et al. Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology (2015) 61(6):1957-67. doi:10.1002/hep.27728.
62. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology (2011) 54(1):173-84. doi:10.1002/hep.24351.
63. Yamada D, Rizvi S, Razumilava N, Bronk SF, Davila JI, Champion MD, et al. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 61(5):1627-42. doi:10.1002/hep.27687.
64. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 128(7):2054-65. doi:10.1053/j.gastro.2005.03.010.
65. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res (2006) 66(21):10517-24. doi:10.1158/0008-5472.CAN-06-2130.
66. Li J, Razumilava N, Gores GJ, Walters S, Mizuochi T, Mourya R, et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 124(7):3241-51. doi:10.1172/JCI73742.
67. Carcas LP. Gastric cancer review. J Carcinog (2014) 13:14. doi:10.4103/1477-3163.146506.
68. Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol (2012) 4(7):156-69. doi:10.4251/wjgo.v4.i7.156.
69. Peek RM Jr, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol (2006) 208(2):233-48. doi:10.1002/path.1868.
70. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest (2007) 117(1):60-9. doi:10.1172/JCI30111.
71. Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ, Hu WH. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig Dis Sci (2015) 60(5):1265-72. doi:10.1007/s10620-014-3463-1.
72. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene (2007) 26(22):3279-90. doi:10.1038/sj.onc.1210421.
73. Wang Z, Si X, Xu A, Meng X, Gao S, Qi Y, et al. Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications. PLoS One (2013) 8(10):e75788. doi:10.1371/journal.pone.0075788.
74. Verma S, Kesh K, Ganguly N, Jana S, Swarnakar S. Matrix metalloproteinases and gastrointestinal cancers: impacts of dietary antioxidants. World J Biol Chem (2014) 5(3):355-76. doi:10.4331/wjbc.v5.i3.355.
75. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (2014) 383(9927):1490-502. doi:10.1016/S0140-6736(13)61649-9.
76. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 319(9):525-32. doi:10.1056/NEJM198809013190901.
77. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology (2010) 138(6):2101.e-14.e. doi:10.1053/j.gastro.2010.01.058.
78. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol (2011) 6:479-507. doi:10.1146/annurev-pathol-011110-130235.
79. Grivennikov SI, Cominelli F. Colitis-associated and sporadic colon cancers: different diseases, different mutations? Gastroenterology (2016) 150(4):808-10. doi:10.1053/j.gastro.2016.02.062.
80. Robles AI, Traverso G, Zhang M, Roberts NJ, Khan MA, Joseph C, et al. Whole-exome sequencing analyses of inflammatory bowel disease-associated colorectal cancers. Gastroenterology (2016) 150(4):931-43. doi:10.1053/j.gastro.2015.12.036.
81. Mager LF, Wasmer MH, Rau TT, Krebs P. Cytokine-induced modulation of colorectal cancer. Front Oncol (2016) 6:96. doi:10.3389/fonc.2016.00096.
82. Cui G, Qi H, Gundersen MD, Yang H, Christiansen I, Sorbye SW, et al. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother (2015) 64(2):181-90. doi:10.1007/s00262-014-1624-x.
83. Mertz KD, Mager LF, Wasmer MH, Thiesler T, Koelzer VH, Ruzzante G, et al. The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology (2016) 5(1):e1062966. doi:10.1080/2162402X.2015.1062966.
84. Zhang Y, Davis C, Shah S, Hughes D, Ryan JC, Altomare D, et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog (2017) 56:272-87. doi:10.1002/mc.22491.
85. Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W, et al. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun (2014) 453(3):486-92. doi:10.1016/j.bbrc.2014.09.106.
86. Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci U S A (2015) 112(19):E2487-96. doi:10.1073/pnas.1422445112.
87. Islam MS, Horiguchi K, Iino S, Kaji N, Mikawa S, Hori M, et al. Epidermal growth factor is a critical regulator of the cytokine IL-33 in intestinal epithelial cells. Br J Pharmacol (2016) 173:2532-42. doi:10.1111/bph.13535.
88. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, et al. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A (2007) 104(50):19977-82. doi:10.1073/pnas.0704620104.
89. Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, Strouch M, et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A (2010) 107(14):6430-5. doi:10.1073/pnas.0913683107.
90. Cheon EC, Khazaie K, Khan MW, Strouch MJ, Krantz SB, Phillips J, et al. Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res (2011) 71(5):1627-36. doi:10.1158/0008-5472.CAN-10-1923.
91. Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg (2003) 90(12):1556-64. doi:10.1002/bjs.4346.
92. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 15(2):103-13. doi:10.1016/j.ccr.2009.01.001.
93. Hu T, Yao Y, Yu S, Guo H, Han L, Wang W, et al. Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer. J Biomed Res (2013) 27(4):283-90. doi:10.7555/JBR.27.20130069.
94. Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y, et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer (2013) 132(2):276-87. doi:10.1002/ijc.27670.
95. Wang TB, Hu BG, Liu DW, Shi HP, Dong WG. The influence of lentivirus-mediated CXCR4 RNA interference on hepatic metastasis of colorectal cancer. Int J Oncol (2014) 44(6):1861-9. doi:10.3892/ijo.2014.2348.
96. O'Donnell C, Mahmoud A, Keane J, Murphy C, White D, Carey S, et al. An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. Br J Cancer (2016) 114(1):37-43. doi:10.1038/bjc.2015.433.
97. Malik A, Sharma D, Zhu Q, Karki R, Guy CS, Vogel P, et al. IL-33 regulates the IgA-microbiota axis to restrain IL-1alpha-dependent colitis and tumorigenesis. J Clin Invest (2016) 126:4469-81. doi:10.1172/JCI88625.
98. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol (2010) 91(2):174-9. doi:10.1007/s12185-010-0529-5.
99. Prick J, de Haan G, Green AR, Kent DG. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. Exp Hematol (2014) 42(10):841-51. doi:10.1016/j.exphem.2014.07.268.
100. Skoda RC, Duek A, Grisouard J. Pathogenesis of myeloproliferative neoplasms. Exp Hematol (2015) 43(8):599-608. doi:10.1016/j.exphem.2015.06.007.
101. Levescot A, Flamant S, Basbous S, Jacomet F, Feraud O, Anne Bourgeois E, et al. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. Cancer Res (2014) 74(10):2669-76. doi:10.1158/0008-5472.CAN-13-2797.
102. Mager LF, Riether C, Schurch CM, Banz Y, Wasmer MH, Stuber R, et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J Clin Invest (2015) 125(7):2579-91. doi:10.1172/JCI77347.
103. Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol (2015) 194(1):438-45. doi:10.4049/jimmunol.1401344.
104. Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res (2014) 74(6):1789-800. doi:10.1158/0008-5472.CAN-13-2729.
105. Rose WA II, Okragly AJ, Patel CN, Benschop RJ. IL-33 released by alum is responsible for early cytokine production and has adjuvant properties. Sci Rep (2015) 5:13146. doi:10.1038/srep13146.
106. Lim HX, Choi S, Cho D, Kim TS. IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Immunol Cell Biol (2017) 95(1):99-107. doi:10.1038/icb.2016.72.
107. Bessa J, Meyer CA, de Vera Mudry MC, Schlicht S, Smith SH, Iglesias A, et al. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. J Autoimmun (2014) 55:33-41. doi:10.1016/j.jaut.2014.02.012.
108. Talabot-Ayer D, Martin P, Vesin C, Seemayer CA, Vigne S, Gabay C, et al. Severe neutrophil-dominated inflammation and enhanced myelopoiesis in IL-33-overexpressing CMV/IL33 mice. J Immunol (2015) 194(2):750-60. doi:10.4049/jimmunol.1402057.
109. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci (2011) 56(12):3596-601. doi:10.1007/s10620-011-1760-5.
110. Hu LA, Fu Y, Zhang DN, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer. Asian Pac J Cancer Prev (2013) 14(4):2563-6. doi:10.7314/APJCP.2013.14.4.2563.
111. Gramatzki D, Frei K, Cathomas G, Moch H, Weller M, Mertz KD. Interleukin-33 in human gliomas: expression and prognostic significance. Oncol Lett (2016) 12(1):445-52. doi:10.3892/ol.2016.4626.
112. Rossle M, Cathomas G, Bonapace L, Sachs M, Dehler S, Storz M, et al. Interleukin-33 expression indicates a favorable prognosis in malignant salivary gland tumors. Int J Surg Pathol (2016) 24(5):394-400. doi:10.1177/1066896916633856.
113. Saranchova I, Han J, Huang H, Fenninger F, Choi KB, Munro L, et al. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker interleukin-33. Sci Rep (2016) 6:30555. doi:10.1038/srep30555.
114. Gluck J, Rymarczyk B, Rogala B. Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. Inflamm Res (2012) 61(6):547-50. doi:10.1007/s00011-012-0443-9.
115. Tamagawa-Mineoka R, Okuzawa Y, Masuda K, Katoh N. Increased serum levels of interleukin 33 in patients with atopic dermatitis. J Am Acad Dermatol (2014) 70(5):882-8. doi:10.1016/j.jaad.2014.01.867.
116. Xia J, Zhao J, Shang J, Li M, Zeng Z, Zhao J, et al. Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol (2015) 308(7):L619-27. doi:10.1152/ajplung.00305.2014.
117. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A (2010) 107(43):18581-6. doi:10.1073/pnas.1003059107.
118. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest (2011) 121(1):396-409. doi:10.1172/jci35721ds1.
119. Qin L, Dominguez D, Chen S, Fan J, Long A, Zhang M, et al. Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget (2016) 7(38):61069-80. doi:10.18632/oncotarget.11179.
120. Xiao P, Wan X, Cui B, Liu Y, Qiu C, Rong J, et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology (2016) 5(1):e1063772. doi:10.1080/2162402X.2015.1063772.
121. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol (2011) 186(7):4375-87. doi:10.4049/jimmunol.1003020.
122. Gordon ED, Simpson LJ, Rios CL, Ringel L, Lachowicz-Scroggins ME, Peters MC, et al. Alternative splicing of interleukin-33 and type 2 inflammation in asthma. Proc Natl Acad Sci U S A (2016) 113(31):8765-70. doi:10.1073/pnas.1601914113.
123. Gangemi S, Allegra A, Profita M, Saitta S, Gerace D, Bonanno A, et al. Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia. Cancer Invest (2013) 31(3):212-3. doi:10.3109/07357907.2013.764566.
124. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A (2007) 104(1):282-7. doi:10.1073/pnas.0606854104.
125. Lee EJ, So MW, Hong S, Kim YG, Yoo B, Lee CK. Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis. Cytokine (2016) 77:35-43. doi:10.1016/j.cyto.2015.10.005.
126. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer (2013) 12:86. doi:10.1186/1476-4598-12-86.
127. Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol (2010) 125(3):752-4. doi:10.1016/j.jaci.2009.12.935.